These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29133496)

  • 21. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
    Dennison EM; Rubin KH; Schwarz P; Harvey NC; Bone KW; Cooper C; Abrahamsen B
    Arch Osteoporos; 2015; 10():36. PubMed ID: 26481934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    Kim JW; Kwak SG; Park SH
    Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
    [No Abstract]   [Full Text] [Related]  

  • 26. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions.
    Coleshill MJ; Day RO; Tam K; Kouhkamari M; Caillet V; Aung E; Kannangara DRW; Cronin P; Rodgers A; Stocker SL
    Br J Clin Pharmacol; 2022 Nov; 88(11):4894-4901. PubMed ID: 35675118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolution of massive tophaceous gout with three urate-lowering drugs.
    Mejía-Chew C; Torres RJ; de Miguel E; Puig JG
    Am J Med; 2013 Nov; 126(11):e9-10. PubMed ID: 23978312
    [No Abstract]   [Full Text] [Related]  

  • 32. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial.
    Satpanich P; Pongsittisak W; Manavathongchai S
    Clin Rheumatol; 2022 Jan; 41(1):213-221. PubMed ID: 34406530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allopurinol and kidney function: An update.
    Stamp LK; Chapman PT; Palmer SC
    Joint Bone Spine; 2016 Jan; 83(1):19-24. PubMed ID: 26453097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
    Kim SC; Schmidt BM; Franklin JM; Liu J; Solomon DH; Schneeweiss S
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2008-14. PubMed ID: 23861232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
    Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
    Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
    Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence with urate-lowering therapies for the treatment of gout.
    Harrold LR; Andrade SE; Briesacher BA; Raebel MA; Fouayzi H; Yood RA; Ockene IS
    Arthritis Res Ther; 2009; 11(2):R46. PubMed ID: 19327147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
    Watson L; Belcher J; Nicholls E; Muller S; Mallen C; Roddy E
    Arthritis Rheumatol; 2020 Nov; 72(11):1928-1935. PubMed ID: 32767502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.